Sign in

CIK 0001130598

  • Non-accelerated filer
  • Smaller reporting company

Traws Pharma, Inc.

Sign in to watch
Ticker
TRAW
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 267-759-3680
Business address
12 PENNS TRAIL, NEWTOWN, PA, 18940
Former names
Onconova Therapeutics, Inc., ONCONOVA THERAPEUTICS INC
  1. 4 Open-market sale President and CEO sold 33,543 shares at an average $15.07 ($505,616)
  2. 4 Open-market sale President and CEO sold 60,000 shares at an average $15.05 ($903,000)
  3. 4 Open-market buy Director bought 57,295 shares at an average $11.92 ($682,689)
  4. 4 Open-market buy 10% owner bought 57,295 shares at an average $11.92 ($682,689)
  5. 4 Derivatives Options or other derivatives
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Exercise or conversion Director acquired 32,036 shares (option exercise)
  10. 4 Open-market buy 10% owner bought 5,000 shares at an average $14.39 ($71,948)
  11. 4 Open-market buy Director bought 5,000 shares at an average $14.39 ($71,948)
  12. 4 Open-market buy Director bought 5,000 shares at $11.87 ($59,350)
  13. 4 Open-market buy 10% owner bought 5,000 shares at $11.87 ($59,350)
  14. 4 Open-market buy Director bought 5,000 shares at $12.10 ($60,500)
  15. 4 Open-market buy Director bought 19,700 shares at an average $11.99 ($236,265)
  16. 4 Open-market buy 10% owner bought 19,700 shares at an average $11.99 ($236,265)
  17. 4 Open-market buy President and CEO bought 1,100 shares at $12.02 ($13,222)
  18. 4 Open-market buy Director bought 1,400 shares at an average $12.17 ($17,038)
  19. 4 Exercise or conversion SVP, Finance & Corp. Develop. acquired 5,000 shares (option exercise)
  20. 4 Open-market buy Director bought 1,000 shares at an average $22.72 ($22,724)

Page 17 of 19 · 373 filings